Lung cancer is the leading cause of cancer death worldwide. 1, 2 Pulmonary neuroendocrine tumors form a distinct group of neoplasms that share characteristic morphological, immunohistochmical, ultrastructural and molecular features. 3 These tumors considerably differ in their biological behaviors, thus, they are classified as either low-grade typical carcinoids, intermediate-grade atypical carcinoids, high-grade large cell neuroendocrine lung cancer, or small cell lung cancer. 3, 4 Small cell lung cancers account for the largest group of these tumors (B15% of all lung malignancies) and are associated with an extremely poor prognosis, [5] [6] [7] [8] whereas large cell euroendocrine cancers and carcinoids are rare. Currently, the 2004 World Health Organization classification of pulmonary neuroendocrine tumors is based on combined architectural patterns considering the two most relevant morphological parameters, that is, the mitotic index and the presence of necrosis, diagnosed by haematoxylin and eosin morphology. 3, 8, 9 However, these tumors represent a broad spectrum of phenotypically distinct entities, and the assignment of a given neuroendocrine lung tumor can occasionally be cumbersome even for experienced pathologists. 3, 9, 10 Thus, reproducible and objective (molecular) diagnostic criteria with clinical and prognostic value need to be established to achieve a more accurate assignment of the various types of pulmonary neuroendocrine tumors. 3 Micro-RNA (miRNA) molecules are evolutionarily conserved, small RNA-molecules with a size of 19-24 nucleotides and, unlike mRNA, do not encode amino-acid sequences. 3, 11, 12 miRNAs function as negative endogenous gene-expression regulators by binding complementary sequences in target mRNAs, resulting in their selective degradation or selective steric inhibition of translation. 2, 3, 12, 13 Therefore, miRNAs are involved in a wide range of biological functions, including cellular proliferation, differentiation, angiogenesis, apoptosis, and metastatic potential. 2, [12] [13] [14] [15] [16] [17] Aberrant miRNA expression has been reported to be involved in the pathogenesis of Alzheimer's disease, 18 cardiovascular disease, 19 spinal motor neuron anomalies, 20 and numerous others. 2 Furthermore, deregulated expression of miRNAs has been identified in a variety of human malignancies, 12, 13, [21] [22] [23] [24] [25] [26] [27] [28] [29] suggesting that miRNAs function as potential oncogenic factors or tumor suppressors, depending on the cell type or tissue investigated and their target genes. 3 For example, the miR-34 family members are direct transcriptional targets of p53 and their expression induces cell cycle arrest in cancer cell lines. 5, 30, 31 miRNA-29 family members act as tumor suppressors through the restoration of a normal DNA methylation pattern. 5, 31 Among other tumor entities, both of these miRNAs are known to be deregulated in nonsmall cell lung cancer. [31] [32] [33] [34] [35] [36] The role of miRNAs in cancer biology, prognosis prediction, and as a diagnostic tool in non-small cell lung cancer without neuroendocrine features has been intensively studied. 3, 5, 37 Besides miR-34 and miR-29 family members, let-7a overexpression, possibly through suppression of the RAS oncogene, was shown to be related to increased overall survival in non-small cell lung cancer patients. 2, 5, [38] [39] [40] In contrast, overexpression of the 'oncomirs' miR-21 and miR-155 was shown to be related to a decreased overall survival in non-small cell lung cancer patients. 2, 5, 39, 41 It has been suggested that miR-31 may act as an oncogenic miRNA by inhibiting the tumor suppressors LATS2 and PPP2R2A, 42 and the expression of miR-205 has been suggested to distinguish squamous from nonsquamous lung cancer. 2, 43 miR-126 may promote lung cancer cells irradiation-induced apoptosis through the PI3K-AKT pathway. 2, 44 However, data on the role of miRNA expression in neuroendocrine tumors of the lung are limited, and the function of several miRNAs, which are well-documented cancer-related miRNAs in other cancer types, has not been investigated in neuroendocrine lung tumors so far. 3, 5 Furthermore, we hypothesized that specific 'biomarker miRNAs' might exist that could distinguish more accurately and reliably between subtypes of pulmonary neuroendocrine tumors. Against this background, 763 different miRNAs in all four different subtypes of neuroendocrine human pulmonary tumors were evaluated.
Materials and methods

Patient Cohort and Study Design
Twelve tumor specimens including three of each typical and atypical carcinoid tumors, large cell neuroendocrine lung cancer, and small cell lung cancer were investigated. The specimens were retrieved from the archives of the Institute of Pathology and Neuropathology of the University Hospital Essen (Germany). All of these tumor specimens were classified as either atypical or typical carcinoids of the lung, large cell lung cancer or small cell lung cancer, respectively. To verify the initial diagnosis, all specimens were reevaluated by two experienced pathologists (JWO, THA). The patients had undergone surgical resection for their lung tumors between 2005 and 2012. In addition, clinical follow-up was available, as well as information about a broad range of other investigations (immunohistochemistry, sequencing-data, and mRNA expression profiles). All the investigated samples contained a sufficient amount of tumor cells for RNA isolation and a low percentage of contaminating benign or desmoplastic stroma cells. The investigations conform to the principles declared in the declaration of Helsinki. This retrospective study was approved by the Ethics Committee of the Medical Faculty of the University Duisburg-Essen (13-5382-BO).
TaqMan qPCR miRNA Assay Cards
Formalin-fixed, paraffin-embedded tissue specimens were used for RNA isolation. Sections of tumor tissue prepared for RNA isolation were stored at À 20 1C until used. Total RNA isolation (including isolation of miRNA) was performed with the 'miRNeasy FFPE' kit from Qiagen (Hilden, Germany) according to the manufacturers' protocol, using adapted times and volumes (eg, overnight digestion). RNA not immediately used was stored at -20 1C until use.
For cDNA synthesis the Megaplex RT Human Primer Pools A and B (Applied Biosystems, Foster City, CA, USA) in combination with the TaqMan miRNA Reverse Transcription Kit (Applied Biosystems) was engaged. cDNA not immediately used was For 384-well TaqMan low-density array real-time qPCR, preamplification products were pressed through microchannels into wells fixed in the card, preloaded with immobilized, dehydrated targetspecific primers-probe pairs. PCR analysis was run on the ABI PRISM 7900 System. Analysis was done with TaqMan Array Human MicroRNA Card A and TaqMan Array Human MicroRNA Card B v3.0 (both Applied Biosystems), respectively. PCR was performed using the ready-to-use TaqMan Universal PCR Master Mix (Applied Biosystems). Of note, qPCR analysis was performed in concordance to the MIQE-guidelines. 45 
Statistical Analysis
Correlation analysis was performed with a customprogrammed algorithm for the R software. The exact Wilcoxon-Mann-Whitney Rank Sum test was used to test associations between miRNA expression and dichotomous variables (eg, gender). To rule out a possible association between miRNA and clinical variables (age, age of blocks, etc), a Spearman's rank correlation test was performed. The Spearman's rank correlation test was done to test associations between tumor type and expression levels of different miRNAs.
Overall survival was compared by performing Kaplan-Meier curves. Survival analysis for overall survival was calculated by Cox-regression (COXPHmodel), statistical significance was determined using Likelihood ratio test and Score (logrank) test.
Because of the better distribution of our expression levels in logarithmic scale, all further analysis were additionally performed using log(miR)-values. A Bonferroni correction for multiple testing was performed to all calculated P-values to overcome the problem of false-positive results in this highthroughput statistics. The level of statistical significance was defined as Po0.05.
Bioinformatics miRNA target-sites were descriptively determined using the miRanda-database (miRanda), inhibition scores were calculated by the mirSVR algorithm. The 10 most strongly regulated miRNA-targets of every miRNA being differently regulated in the various neuroendocrine tumors were selected for further analysis. In addition, all targets with a score over 2.00 were selected for the identification of possible deregulated pathways. Associated pathways, which were affected by differences in the miRNA expression levels, were discovered and, if possible, correlated to gene-and protein expression levels already available. In addition, a gene ontology (GO)-term analysis to classify differentially regulated biological processes was performed.
Databases used for pathway identification are uniprot.org and the NCBI website gene-search and BioSystems-search, respectively.
Results
qPCR analysis was accomplished successfully in all cases. The endogenous control always showed up between Ct 12.5 and 13.9 on both plates.
In the entire cohort of patients including typical and atypical carcinoids, large cell neuroendocrine cancers and small cell lung cancers, 44 significantly differently expressed miRNAs could be identified. For 11 of these differently expressed miRNAs, the level of statistical significance was o0.01. Seven of these miRNAs (miR-22, miR-29a, miR-29b, miR-29c, miR-367*; miR-504, miR-513C, miR-1200) were negatively correlated to biological aggressiveness (determined by tumor grade), for the remaining four miRNAs a positive correlation with tumor biology (miR-18a; miR-15b*, miR-335*, miR-1201) was observed (data are summarized in Table 1 ).
miR-18a was significantly correlated with the tumor grading, that is, being lowest in typical and increasing in atypical carcinoids to large cell neuroendocrine lung cancer, and being highest in small cell lung cancer, showing a 20.25-fold higher expression in high-grade neuroendocrine pulmonary tumors compared with carcinoid tumors. Similar observations were made for miR-15b* and miR-335*, 5.25-fold and 4.62-fold, respectively). miR-22 expression decreased 412 times from typical to atypical carcinoids and large cell carcinoma (both showed identical expression levels) and again 412 times to small cell lung cancer (overall decrease from carcinoids to carcinomas: 23.9-fold). Moreover, miR-29a, miR-29b, and miR-29c expression levels decline with increasing aggressiveness of the tumor. They demonstrated almost identical expression levels in carcinoids and the expression levels significantly decreased in large cell carcinoma and further to small cell lung cancer. miR-504 expression was rather stable in carcinoids and large cell lung cancer but was completely abolished in small cell cancer. miR-367* showed a similar pattern of expression compared with miR-22, but the inverse correlation with aggressiveness was much stronger (typical carcinoid/typical carcinoid: B21.85-fold; large cell cancer/small cell cancer: B28.22-fold). Expression of miR-513C was only detected in typical carcinoids, but was significantly decreased to a minimum in atypical carcinoids and high-grade neuroendocrine lung cancers. miR-1201 was stably expressed in both carcinoids, but its expression increased in high-grade neuroendocrine lung cancers (Figure 1 ).
Forty-five miRNAs were identified showing a significant impact on survival time. Highly significant associations were noted for nine miRNAs using the Likelihood ratio test and the Score (logrank) test (let-7d; miR-139-5p; miR-197; miR-301; miR-576-5p; miR-582-5p; miR-448; miR-340*; miR-1286). Five miRNAs were still significantly associated with survival if an additional Wald test was performed (let-7d; miR-19; miR-576-5p; miR-340*; miR-1286). Data are summarized in Table 2 .
In this cohort it was observed that the increasing malignant potential of the tumors was correlated with the differential expression of miRNAs leading to pathway upregulation. The pathway affected the most was the extracellular signal-regulated kinase (ERK)/MAPK-signaling pathway. Also in the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway, which is involved in different cellular processes, significant differences in miRNAs expression between the four tumor types of pulmonary neuroendocrine tumors were noted. Furthermore, the TGF-beta pathway becomes activated with increasing potential for the development of metastasis, indicating a causative relation between augmented angiogenesis and more frequent development of metastatic disease in these tumors. In addition, the Wnt-signaling pathway, NFkB pathway, JNK-MAPKsignaling network as well as the mTOR-complex associated signaling was differentially regulated by miRNA expression (Figure 2) .
The GO analysis revealed 256 hits at regulation of gene expression and transcriptional regulation. The next major differentially regulated field of cellular processes was cell cycle regulation (139 hits) followed by the development and differentiation of the nervous system, more precisely the part of neuronal development (134 hits). In addition, proliferation (125 hits), immune response (105 hits), apoptosis (96 hits), and DNA repair (59) were strongly deregulated in this collection of neuroendocrine lung cancer specimens. Furthermore, growth factors as well as growth-factor receptors and their pathways were clearly affected (53 hits). Less, but also differentially regulated were processes such as ion uptake/carrier-depended uptake of compounds and angiogenesis (48 and 42 hits, respectively). Moreover, there was a strongly aberrant regulation of the expression of structural cell compounds (42 hits), especially of collagens (19 hits) (Figure 3 ).
Discussion
Despite the accuracy of diagnostic methods used in modern pathology has dramatically improved, the discrimination between the different subtypes of neuroendocrine lung tumors remains challenging. Especially the differential diagnosis between atypical carcinoids and small cell lung cancers as well as the differentiation between small cell lung cancer and large cell neuroendocrine lung cancer can need supporting molecular-biological facts. To improve this discrimination, the establishment of reliable markers for the differentiation between different subtypes of neuroendocrine pulmonary tumors in routine pathology is desirable. This study was designed to test the miRNA profiles of these lung cancer types in order to establish feasible and reliable markers that facilitate finding correct diagnosis in routine diagnostic surgical pathology. At present, the diagnosis of the different types of neuroendocrine lung tumors is usually based on morphological and histological findings. The miR-513C has a strong diagnostic impact to discriminate between typical and atypical carcinoids; miR-504 can be a supporting diagnostic tool for discrimination of large cell neuroendocrine lung cancer and small cell lung cancer. miR18a and miR-1201 are much highly expressed in carcinomas than in carcinoids, also miR-15b* and miR-335* show higher expression in HG than in LG tumors. In contrast, miR-22 and miR-367* are less expressed in HG than in LG NET of the lung.
identification of a clear-cut correlation between the expression of a defined set of miRNAs and a given neuroendocrine tumor type would be of benefit for both the diagnostic process and individualization of therapeutic concepts. Also when isolated from formalin-fixed, paraffin-embedded tissue, RNA can be a useful and robust marker rendering reproducible results. 46 In addition, miRNAs are highly stable also in formalin-fixed tissue and, therefore, can be used for normal pathological routine diagnostic purposes. 47 In the past, some miRNAs were found to distinguish between different types of lung tumors, having a crucial role in the tumorgenesis of lung cancers and/or having a prognostic or predictive impact on these tumors. However, the majority of these studies focused on non-small cell lung cancer patients, whereas data concerning pulmonary neuroendocrine tumors are still lacking. Expression of the miR-29 family was inversely correlated to an increasing degree of malignant behavior in our cohort of patients. Decreased expression was associated with an increasing aggressive biological behavior. In large cell neuroendocrine lung cancers, the expression of miR-29 family members is known to be strongly correlated with the DNA methylation pattern of tumor cells, because the miR-29 family members target the DNAmethyltransferases 3A and 3B (DNMT3A/DNMT3B). Their function is required for the de novo methylation and for the establishment of DNA methylation patterns during development. Therefore, a high methylation pattern is present, but an induced expression of miR-29 restores normal pattern and reexpression of silenced tumor suppressor genes like fragile histidine triad in cell lines. 31 Finally, this leads to a reprogramming of tumor cells to the physiological state, which indicates that, the miR-29 family (especially miR-29a, miR-29b, and miR-29c) act as tumor-suppressor-miRNAs. 31 Furthermore, this mechanism might explain why downregulation of miR-29 expression is accountable for hypermethylation and frequent silencing of tumor suppressor genes. Although the expression levels in carcinoids were almost identical, there was a huge difference between low and high-grade neuroendocrine lung tumors as well as between large cell neuroendocrine lung cancer and small cell lung cancer (Figure 2) . Furthermore, other targets of the miR-29 family are p85a and CDC42. 48 CDC42 and p85a are negative regulators of p53, which has apoptotic activity. Lower miR-29 expression decreases p53 levels resulting in escape from apoptosis and is associated with biologically malignant behavior. miR-34 family members are suspected to be associated with the p53 tumor suppressor network to inhibit inappropriate cell proliferation. 30 Nevertheless, no significant difference in the miR-34 expression levels between the four types of neuroendocrine tumors could be outlined in this study. Our findings are consistent with a report from Lee et al 5 demonstrating that none of the miR-34 family members could be used as a prognostic marker in neuroendocrine lung cancers, including small cell lung cancer. Members of the miRNA family let-7 are also thought to be deregulated in human lung cancers, including cancers with neuroendocrine differentiation. 3, 12 However, in this study, these miRNAs were not able to discriminate between the different subtypes of neuroendocrine lung tumors. Thus, we were unable to confirm the association observed in other retrospective studies. 2, 5, [38] [39] [40] The let-7d expression was significantly associated with overall survival, suggesting that let-7d could have an important role in metastasis and tumor progression. The miRNAs miR-21 and miR-155, both reported to be overexpressed in neuroendocrine lung cancers, 1, 3 did not show a significant association with overall survival in our cohort. Similar results were revealed for miR-210, a miRNA overexpressed in cancer tissue vs normal lung parenchyma. 1 Especially miR-21 turns out to be an interesting target, because it is a key regulator of the mTOR pathway and is reported to be differentially regulated in neuroendocrine tumors. 49 In addition, miR-96 expression co-induces the methylation pattern of normal cells and is upregulated in non-small cell lung cancer. 2 Nevertheless, we were unable to confirm that miR-96 is a potential diagnostic marker whose expression differs between the neuroendocrine tumor types. In this context, the differential expression of the miR-143 in the different tumor types was reported. miR-143 targets mainly the hexokinase 2 gene, which is the key regulator of glycolysis activated in multiple human cancers. 50 If the malignant potential increases, the expression of miR-143 decreases leading to an augmented glycolytic activity of the tumors (Warburg effect). High-grade neuroendocrine cancers with an increased proliferative activity require a stronger metabolic activity and depend on the glycolytic utilization of glucose. However, the expression of miR-375 did not differ significantly between the various tumor types. miR-375 is a key downstream effector of achaetescute homolog 1 (ASH1)-mediated induction of Figure 2 Results of the pathway analysis, depending on gene regulation owing to miRNA expression pattern between the four types of NELC. The two most affected pathways are the MAPK-signaling pathway and the PI3K-pathways, followed by TGF-beta-and WNTsignaling. Figure 3 Results of the GO analysis. Mostly affected GO-term were gene expression/transcription, followed by cell cycle, nervous system/neuronal development, proliferation, immune response, and apoptosis. neuroendocrine features. The transcriptional coactivator of ASH1, YAP1, was determined to be a direct target of miR-375. 37 ASH1 is a proneural basic helix-loop-helix transcription factor, leading to an exhibition of neuroendocrine features. 51 In addition, a functional knockdown of ASH1 elicits prominent apoptosis in lung cancer cell lines with neuroendocrine features. 52 Considering the results of the pathway analyses, in which the investigated miRNAs are involved, the MAPK pathway was identified to be the most affected signal transduction pathway. MAPK pathway is one of the most important evolutionary conserved intracellular signaling cascades. 53, 54 MAPKs are intracellular serine/threonine kinases 55 and the three most intensively studied kinases are the ERK, c-jun NH2-terminal kinase, and p38. 53, 56, 57 Kit, proteinkinase B (PKB)/Akt and MAPK are expressed in a high percentage of small cell lung cancers. 55 Furthermore, miRNAs targeting the PI3K/ Akt/mTOR signaling pathway were differentially expressed in the four types of pulmonary neuroendocrine tumors investigated in this study.
It has to be kept in mind that the number of patients included is small and the results have to be regarded as a pilot. Owing to the excellent results, however, the proof of our findings in a larger cohort seems highly desirable.
In conclusion, the different subtypes of neuroendocrine lung tumors (typical carcinoids, atypical carcinoids, large cell neuroendocrine lung cancer, and small cell lung cancer) demonstrate significant differences in their miRNA expression profile. Moreover, significant insight into the molecular biology of pulmonary neuroendocrine tumors can be derived from these data. These might potentially be able to be used for diagnostic purposes and the assessment of prognosis. In particular, the expression of miR-29 family members is decreased paralleling an increasing grade of malignancy of the tumor. miRNA targeting protein expression of the MAPK and PI3K signaling pathways are differentially expressed in the various pulmonary neuroendocrine tumor subtypes. These data might prompt further scientific effort to explore potential novel therapeutic approaches for the treatment of these tumors. Nevertheless, a validation of these results on a bigger collective is urgently needed before these markers can be de facto integrated in a routine diagnostical setting.
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